(GMDA) – Press Releases
-
XORTX Welcomes New Member to the Board of Directors
-
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
-
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
-
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
-
Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results
-
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
-
Gamida Cell Actively Pursuing Strategic Alternatives
-
Gamida Cell to Present at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
-
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
-
Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023
-
Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference
-
Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update
-
Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
Gamida Cell to Report Third Quarter 2023 Financial Results
-
Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201
-
Gamida Cell Issues Update on Israel Operations
-
Gamida Cell to Present Corporate Highlights at 2023 Cell & Gene Meeting on the Mesa
-
Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
-
First Patient Receives Gamida Cell's Omisirge™ (omidubicel-onlv)
-
Gamida Cell to Present Corporate Highlights at the H.C. Wainwright 25th Annual Global Investment Conference
-
Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update
-
Gamida Cell to Report Second Quarter 2023 Financial Results
-
Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell’s Omisirge® (omidubicel-onlv)
-
STAND UP TO CANCER NAMES JULIAN ADAMS, Ph.D., CHIEF SCIENCE OFFICER
-
Gamida Cell To Host Investor Day
-
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
-
Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual Meeting
-
Gamida Cell Appoints Terry Coelho as CFO
-
Gamida Cell Reports First Quarter 2023 Financial Results and Provides Company Update
-
Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast
-
Gamida Cell Announces Pricing of $23 Million Public Offering of Securities
-
Gamida Cell Announces Launch of Public Offering of Securities
-
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval
-
Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update
-
Gamida Cell Announces Changes to Board of Directors
-
Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast
-
Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference
-
Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR
-
Gamida Cell Announces Closing of $25 Million Financing With Highbridge
-
Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
-
Gamida Cell Provides Regulatory Update on Omidubicel
-
Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update
-
Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference
-
Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast
-
GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers
-
Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting
-
Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa
-
Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting
-
Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing
-
Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares
Back to GMDA Stock Lookup
